Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Inclusion Criteria: \* Patients with: non-Hodgkin's lymphoma, Hodgkin's disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, or multiple myeloma \* Eligible for fractionated total body irradiation (fTBI) plus high-dose chemotherapy followed by autologous PBPC support. \* 18 years of age or older \* Karnofsky performance status greater than or equal to 70% \* Minimum of 1.5 Mio CD34+ cells/kg cryopreserved and to be transplanted \* Informed consent for participation in the study Exclusion Criteria: \* History of, or concurrent cancer other than NHL, Hodgkin's disease, AML, ALL, CML, CLL, multiple myeloma \* Prior bone marrow or peripheral blood stem cell transplantation \* Purged stem cell product \* Currently active infection or oral mucositis \* Congestive heart failure \* Serum creatinine \> 1.5x ULN \* Direct bilirubin \> 1.5x ULN \* Transaminases \> 3x ULN \* Corrected DLCO \< 50% of predicted \* Subject is currently enrolled in, or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s). \* Subject is pregnant (eg, positive human chorionic gonadotropin \[HCG\] test) or is breastfeeding. \* Subject refuses to use adequate contraceptive precautions. \* Known hypersensitivity to any of the products to be administered during dosing, including E coli-derived products. \* Inability to give a truly informed consent.